Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use

A compound represented by the Formula I:

• wherein:
• R1 is a substituted or unsubstituted pyrazine;
• X is selected from the group consisting of CH2, O, S, and NH;
• Y is selected from the group consisting of CH2, O, and S, provided that at least one of X and Y is CH2, or X and Y together with the bond there-between form a cyclopropyl;
• R2 and R3 are independently selected from the group consisting of hydrogen, methyl, halogen, trifluoromethyl, and cyano;
• and
• R4 is selected from the group consisting of
• where R5 is selected from the group consisting of substituted and unsubstituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O—R7, NR8R9, C1-C8 alkyl, and monocyclic heterocycloalkyl, R6 is selected from the group consisting of substituted and unsubstituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, alkenyl, O—R7, C(O)R7, NR8R9, C2-C8 alkyl, and monocyclic heterocycloalkyl, where R7 is selected from the group consisting of substituted and unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, R8 is selected from the group consisting of hydrogen, and substituted and unsubstituted alkyl, and R9 is selected from the group consisting of substituted and unsubstituted alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;
• or a pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt thereof.